Oncolytics Biotech (ONCY) said the FDA granted Fast Track designation for Pelareorep in combination with a checkpoint inhibitor for second-line and later anal cancer. The regulatory milestone supports potential accelerated development of the immunotherapy program, typically improving prospects for future trial execution and review timelines.
Oncolytics Biotech (ONCY) said the FDA granted Fast Track designation for Pelareorep in combination with a checkpoint inhibitor for second-line and later anal cancer. The regulatory milestone supports potential accelerated development of the immunotherapy program, typically improving prospects for future trial execution and review timelines.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
